Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
A single dose, two treatments (Postinor-2 and Opxion), two periods, two sequences, crossover,
randomized, prospective design was chosen with a washout of 14 days between the two study
periods. Treatment groups are balanced with the same number of male healthy volunteers who
were randomly assigned to the study drug administration sequences.